Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Indaptus Therapeutics develops systemic immunotherapies utilizing attenuated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immune responses against cancer and viral infections. Its platform aims to induce broad, durable anti-tumor and antiviral activity without targeting specific antigens, reducing systemic toxicity. The company advances clinical trials for solid tumors, collaborates on combination therapies, and seeks regulatory approval, leveraging proprietary bacterial technology to enhance immunotherapy efficacy across multiple indications.
This description was generated via AI from an annual report. Updated about 1 year ago.